Volume led growth; margins solid but Sahyadri integration remains a lever

Delivered ₹3,090.6 Cr; growth claim unverified (no prior-year detail in delivered data)

Management calculated metric; no prior-year EBITDA in delivered data; claim consistent with 24.2% OPM

Delivered OPM 23.3% (network-wide, all-in); ex-Sahyadri 25% implies Sahyadri ~17% drag, consistent with ₹58 Cr EBITDA on ₹332 Cr revenue (17.5% margin)

23% of ₹3,091 Cr = ₹711 Cr; claim corroborated

Not in delivered result; call detail only; claim internally consistent with 65% occupancy (+290 bps) and ALOS 2.7 days (best-in-class)

Acquired Jan 2026 at ~8-10% EBITDA margin; now 17.5% in Q1 FY27 after 7 months. Doctor interoperability (58 clinicians across brands), clinical mix upgrade, service standards early wins. Path to 25% (ex-Sahyadri network) credible over 18-month integration.

Yelahanka (North Bangalore greenfield) broke even in month 2 of operations (vs management plan of 12+ months). Kanakapura (month 5) at 13% EBITDA margin. Both 6-7 months old; trajectory favorable for full-year margin profile.

Digital now 23% of revenue (₹710 Cr) vs prior base lower; e-pharmacy 15,000 orders Q1, telehealth 17,000 virtual consultations, MAI chatbot 9,600 interactions. Out-of-hospital earnings becoming material revenue stream.

Network at 65% occupancy despite 2.7-day ALOS (best-in-class). 290 bps YoY increase shows demand momentum. Significant room to grow within existing bed base before capex ramp needed.

18-month playbook: doctor interoperability (58 clinicians shared), regional HR structure, clinical mix upgrade (CONGO-R), service standards. Volume-led growth already delivering; integration initiatives cascading into efficiencies. Full rechristening 14-16 months from integration start.

One-off ₹15 Cr contract reversal last year (~0.6%); greenfield doctor cost impact ~0.5% (Kanakapura, Yelahanka fully staffed pre-ramp); scheme collection delays. Excluding one-offs, ~0.9% impact. Greenfiled leverage to normalize by H2 as patient volumes ramp.

Two greenfields (Kanakapura, Yelahanka) operating in Q1, fully staffed: doctor cost ~0.5% drag to network; collection delays ~0.4% (sector-wide). Kanakapura broke even month 5, Yelahanka month 2, both ahead of plan. 13% EBITDA margin already in Q1. No structural concern.

Volume-led growth (IP +39%, OP +26%) is secular tailwind. CONGO-R growing 45%, complexity-mix improving, occupancy headroom clear. Not guiding specific number, but trends (volume, complexity, greenfield ramp) are structural, not seasonal.

Started at 4.2-4.3 years ago; eliminated admin inefficiencies (60% of excess ALOS non-clinical). Government mix 14% (higher ALOS drag), international growth 55% YoY (still 3% revenue). Focus on discharge turnaround; planned discharge process, cash/insurance coordination cuts unnecessary bed days.

Net debt/EBITDA now 2.8x; post Q2 repayment: 0.9x. Comfortable 1.5-2x range (industry average). FY27 capex ₹2,000 Cr (₹900 Cr spent Q1). Over 3-4 years adding 3,000 beds: ₹4,000 Cr total capex. Will use debt opportunistically.

Kinder current run-rate ₹3-4 Cr/month (~₹36-48 Cr annual), margins immaterial. Whitefield is high-growth micro-market; Manipal has 2 large hospitals already performing well. Adding 100 beds creates 3rd location cluster, extends capacity in a growth geography. Will remodel to multispecialty (6-7 months), not build on women/child.

AMRI +17% revenue, Medica +15% Q1 vs prior year. East region (AMRI + Medica + Columbia Asia) +17% topline but cash/TPA +22% (government mix flattening due to scheme transition). Dhakuria facility getting extra beds + integrated oncology program next quarter. On trajectory for margin improvement per plan.

No plans. MHE remains focused on tertiary/quaternary care hospitals. Medical colleges dilute focus; prefer specialty provider model, Centres of Excellence, national leadership in complex procedures. That clarity is our moat.

Bed capacity (13,000→15,000+ beds), occupancy headroom (65% current, 35% to go), CONGO-R mix upgrade (45% IP growth), Sahyadri margin uplift (17.5%→25%), greenfield ramp (Bangalore, Raipur, Juhu, Wakad pipeline), operating efficiency (material, ALOS, digital). Also inorganic (Kerala, NCR, Hyderabad expansion optionality post deleveraging).

Q1 ex-Sahyadri core growth 23%; management cited volume, complexity, greenfield ramp as secular tailwinds. Capex ₹2,000 Cr FY27 for 1,000+ bed additions (Electronic City Q2, Raipur Q4, Kinder mid-year). Not formally guiding, but trajectory strong.

Management has delivered 25% ex-Sahyadri; greenfield doctor cost impact ~0.5% normalizing by H2; collection delays sector-wide. Sahyadri margin expansion to 25% over 18 months is the key lever (currently 17.5%, 800 bps gap).

₹900 Cr spent Q1 (front-loaded). Pipeline visible: Electronic City +300 (Q2), Raipur +300 (Q4), Kinder +100 (mid-year), Wakad Pune +beds, Ahilya Nagar +80 (FY28). Mumbai Juhu (largest, 700+ beds) follows post-FY27.

₹2,000 Cr FY27 capex on 1,000+ bed additions. Kanakapura, Yelahanka beating timelines, but scaling 5+ greenfields simultaneously (Raipur, Juhu, Wakad, Kinder, Ahilya Nagar) over next 3 years requires operational excellence. Early wins don't guarantee full pipeline success.

Sahyadri at 17.5% EBITDA margin (₹58 Cr on ₹332 Cr revenue). Target is 25% portfolio level, 800 bps gap. 18-month integration timeline is aggressive; full brand rechristening 14-16 months dependent on IT systems, staff alignment, service standard rollout. Delay or inefficiency could push margin uplift into FY28+.

East region (AMRI, Medica, Columbia Asia) seeing government scheme transition. Scheme changing from current state plan to national scheme; timing uncertain (on anvil). Cash/TPA business grew 22% despite flat government mix; if scheme shift delays, cash/TPA upside is only offset. Margin risk if scheme reimbursement is lower.

Network at 65% occupancy; volume-led growth thesis depends on continued occupancy increase and ALOS stability at 2.7 days. Any macro slowdown (elective surgeries defer) or clinical protocol change could pressure volumes. ALOS at 2.7 is best-in-class; risk of further compression is low but upside is also limited.